EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss

Axel Chemla iD, Giuseppe Arena iD, Ginevra Sacripanti, Kyriaki Barmpa, Alise Zagare iD, Pierre Garcia, Vyron Gorgogietas, Paul Antony iD, Jochen Ohnmacht iD, Alexandre Baron, Jaqueline Jung, Frida Lind-Holm Mogensen und 8 weitere

Brain · 2025

DOI: 10.1093/brain/awaf051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Axel Chemla und 19 weiteren Autor:innen. Beteiligte Einrichtung: Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg. Hauptthemen laut MEDLINE: rho GTP-Binding Proteins, Dopaminergic Neurons, Parkinson Disease, Mitochondria. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds National de la Recherche Luxembourg, Michael J. Fox Foundation, Horizon 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complex and heterogeneous nature of Parkinson's disease (PD) is still not fully understood. However, increasing evidence supports mitochondrial impairment as a major driver of neurodegeneration. Miro1, a mitochondrial GTPase encoded by the RHOT1 gene, is involved in mitochondrial transport, mitophagy and mitochondrial calcium buffering, and is therefore essential for maintaining mitochondrial homeostasis. Recently, Miro1 has been linked genetically and pathophysiologically to PD, further supported by the identification of heterozygous variants of Miro1 in patients. Herein, we used patient-derived cellular models alongside knock-in mice to investigate Miro1-dependent pathophysiological processes and molecular mechanisms underlying neurodegeneration in PD. Experimental work performed in induced pluripotent stem cell (iPSC)-derived models, including midbrain organoids and dopaminergic neuronal cell cultures from a PD patient carrying the p.R272Q Miro1 mutation as well as healthy and isogenic controls, indicated that the p.R272Q Miro1 mutation leads to increased oxidative stress, disrupted mitochondrial bioenergetics and altered cellular metabolism. These changes were accompanied by increased α-synuclein levels and a significant reduction of dopaminergic neurons. Moreover, the p.R272Q Miro1 mutation—located in the calcium-binding domain of the GTPase—disrupted calcium homeostasis, resulting in calcium-dependent activation of calpain proteases and the subsequent cleavage of α-synuclein. Knock-in mice expressing p.R285Q Miro1 (the murine orthologue of the human p.R272Q mutation) displayed accumulation of phosphorylated α-synuclein in the striatum and a significant loss of dopaminergic neurons in the substantia nigra pars compacta, accompanied by behavioural alterations. These findings demonstrate that mutant Miro1 is sufficient to comprehensively model PD-relevant phenotypes in vitro and in vivo, reinforcing its pivotal role in PD pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho GTP-Binding ProteinsDopaminergic NeuronsParkinson DiseaseMitochondriaMitochondrial ProteinsAnimalsHumansMiceMutationInduced Pluripotent Stem CellsMaleFemalealpha-SynucleinOxidative StressMice, Inbred C57BL

Stichwörter der Autor:innen

calcium homeostasisknock-in miceneurodegenerationp.R272Q Miro1patient-specific iPSC-derived modelsα-synuclein

Substanzen

rho GTP-Binding ProteinsRHOT1 protein, humanMiro-1 protein, mouseMitochondrial Proteinsalpha-Synuclein

Autor:innen und Institutionen

  • Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.
  • Luxembourg Center of Neuropathology (LCNP), Laboratoire National de Santé, L-3555, Dudelange, Luxembourg.
  • Transversal Translational Medicine, Luxembourg Institute of Health (LIH), L-1445 Strassen, Luxembourg.
  • Institute of Medical Genetics and Applied Genomics, University of Tübingen, 72076 Tübingen, Germany.
  • Faculty of Science, Technology and Medicine, University of Luxembourg, L-4365 Esch-sur-Alzette, Luxembourg.
  • Department of Cancer Research, Luxembourg Institute of Health (LIH), L-1210 Luxembourg, Luxembourg.

ORCID-Profile: Axel Chemla, Giuseppe Arena, Alise Zagare, Paul Antony, Jochen Ohnmacht, Manuel Buttini, Thorsten Schmidt, Anne Grünewald, Jens C Schwamborn, Cláudia Saraiva

Förderung

  • Fonds National de la Recherche Luxembourg
  • Michael J. Fox Foundation
  • Horizon 2020

Zitieren

APA

Chemla, A., Arena, G., Sacripanti, G., Barmpa, K., Zagare, A., Garcia, P., Gorgogietas, V., Antony, P., Ohnmacht, J., Baron, A., Jung, J., Lind-Holm Mogensen, F., Michelucci, A., Marzesco, A. M., Buttini, M., Schmidt, T., Grünewald, A., Schwamborn, J. C., Krüger, R., & Saraiva, C. (2025). Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss. Brain. https://doi.org/10.1093/brain/awaf051

Vancouver

Chemla A, Arena G, Sacripanti G, Barmpa K, Zagare A, Garcia P, et al. Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss. Brain. 2025. doi:10.1093/brain/awaf051

BibTeX
@article{Chemla2025,
  author = {Chemla, Axel and Arena, Giuseppe and Sacripanti, Ginevra and Barmpa, Kyriaki and Zagare, Alise and Garcia, Pierre and Gorgogietas, Vyron and Antony, Paul and Ohnmacht, Jochen and Baron, Alexandre and Jung, Jaqueline and Lind-Holm Mogensen, Frida and Michelucci, Alessandro and Marzesco, Anne-Marie and Buttini, Manuel and Schmidt, Thorsten and Grünewald, Anne and Schwamborn, Jens C and Krüger, Rejko and Saraiva, Cláudia},
  title = {Parkinson’s disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awaf051}
}
Kostenlos starten →